Efficacy and toxicity outcomes of total neoadjuvant FLOT versus perioperative FLOT in resectable gastric cancer: Results from the Turkish Oncology Gastrointestinal Cancer Working Group. This is an ...
AstraZeneca's cancer immunotherapy Imfinzi has been approved in the EU for use before and after surgery for early-stage ...
Interactive Use of Cox Model–Predicted Survival Curves: An Application Using ACS10 Score and Age to Personalize Treatment of Pediatric AML Using multicenter observational data (2010-2022), we emulated ...
Reviewed by Anuj K. Patel, MD, Clinical Director of the Center for Esophageal and Gastric Cancer at the Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School in ...
The MATTERHORN trial showed improved EFS and OS with durvalumab plus chemotherapy in gastric/GEJ cancer patients compared to chemotherapy alone. Durvalumab treatment resulted in a higher pCR rate and ...
Promising new approaches to treating gastric cancer have emerged in recent years. These treatments aim to increase patient survival, with reduced toxicity and fewer side effects. Immunotherapies work ...
Obesity significantly elevates the risk of stomach cancer by promoting chronic inflammation, hormonal imbalances, and oxidative stress. Excess body fat disrupts metabolic processes, making the stomach ...
"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results